Teclistamab is a bispecific antibody that targets both CD3 expressed on the surface of T cells and BCMA expressed on the surface of myeloma cells, mediating T-cell activation and subsequent lysis of BCMA-expressing myeloma cells. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.